Related Experiment Video
Updated: Feb 26, 2026
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents
Xin-Wen Xie1, Ren-Zhong Wan2, Zhao-Peng Liu1
1Institute of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, P.R. China.
Abstract:
Matrix metalloproteinase-13 (MMP-13) plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). The subtle differences between the S1' loop of MMP-13 and that of other MMPs offer a structural base for the design of selective MMP-13 inhibitors to mitigate the unperceived risk associated with inhibiting other MMP isoforms. In this review, we summarize zinc-binding and non-zinc-binding selective MMP-13 inhibitors. The zinc-binding MMP-13 inhibitors contain a small set of zinc-binding groups (ZBGs), including hydroxamic acid, pyrimidinetrione, reversed hydroxamic acid and hydantoin, carboxylic acid, 1,2,4,-triazole, and 1,2,4,-triazolone. The non-zinc-binding MMP-13 inhibitors have different structural scaffolds, including diphenyl ethers, biaryls (aryltetrazoliums, arylfurans, pyrazole-indoles), pyrimidines, and aryl/cycloalkyl-fused pyrimidines. This review provides a systematic overview of recent developments in MMP-13 inhibitors for the treatment of OA, with emphasis on their enzyme inhibitory potency, selectivity, and biological activities, and highlights the various binding modes of typical inhibitors with MMP-13.
Insights
Selective matrix metalloproteinase-13 (MMP-13) inhibitors are crucial for treating osteoarthritis (OA) by targeting collagen degradation. This review details zinc-binding and non-zinc-binding inhibitors, offering insights for OA drug development.
Area of Science:
- Biochemistry
- Pharmacology
- Structural Biology
Background:
- Matrix metalloproteinase-13 (MMP-13) is implicated in type II collagen degradation in osteoarthritis (OA).
- Structural distinctions in the MMP-13 S1' loop enable the design of selective inhibitors.
- Inhibiting other MMPs carries potential risks, underscoring the need for MMP-13 specificity.
Purpose of the Study:
- To systematically review selective MMP-13 inhibitors for OA treatment.
- To categorize inhibitors based on zinc-binding groups (ZBGs) and structural scaffolds.
- To emphasize inhibitor potency, selectivity, biological activity, and binding modes.
Main Methods:
- Literature review of zinc-binding and non-zinc-binding MMP-13 inhibitors.
- Analysis of inhibitor chemical structures and their interaction with MMP-13.
- Evaluation of reported enzyme inhibitory data, selectivity profiles, and in vivo/in vitro biological activities.
Main Results:
- Zinc-binding inhibitors utilize groups like hydroxamic acid, pyrimidinetrione, and triazole.
- Non-zinc-binding inhibitors feature scaffolds such as diphenyl ethers, biaryls, and pyrimidines.
- Diverse binding modes of inhibitors with MMP-13 were identified, correlating with potency and selectivity.
Conclusions:
- Selective MMP-13 inhibitors represent a promising therapeutic strategy for OA.
- Understanding inhibitor structures and binding interactions is key to optimizing drug design.
- Further research into MMP-13 inhibitors can lead to improved OA management.
